VIFOR-PHARMA
31.8.2021 07:02:05 CEST | Business Wire | Press release
Regulatory News:
Vifor Pharma is pleased to announce that the European Society of Cardiology (ESC) included new recommendations and proposals in the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure for two of their key products, Ferinject® and Veltassa® .
With regard to iron deficiency, the following new recommendations for HF patients with reduced function of the heart are added:
- Periodic screening for iron deficiency is recommended in all HF patients (Class I).
- Ferinject® should be considered to reduce the risk of HF hospitalizations in symptomatic HF patients with iron deficiency (Class IIa).
- Ferinject® should be considered before and early after discharge in patients who have been hospitalized with acute heart failure and with iron deficiency to improve HF symptoms and reduce risk of re-hospitalizations (Class IIa).
The existing recommendation to consider Ferinject® in patients with HF and iron deficiency to alleviate HF symptoms, improve exercise capacity and quality of life remains unchanged (Class IIa designation). The results of the AFFIRM-AHF study are reflected in the update of the ESC guidelines. Ferinject® remains the only intravenous (i.v.) iron therapy specifically mentioned in the new ESC HF guidelines.
The guidelines also propose that the use of potassium binder agents like Veltassa® may allow RAAS inhibitor initiation or uptitration in a larger proportion of heart failure patients. In patients with chronic or recurrent hyperkalemia on RAAS inhibitor therapy Veltassa® may as well be initiated to maintain the patients on guidelines recommended doses of RAAS inhibitors. The new proposals further describe the unique evidence for RAASi enabling generated by Veltassa® through the clinical trials.
“We are very pleased with the new recommendations to the ESC’s guidelines in heart failure and are grateful for this development for the patients,” commented Klaus Henning Jensen, Chief Medical Officer of Vifor Pharma. “With improved diagnosis rates of iron deficiency and enabling RAASi, more patients can benefit from treatment. Reducing the risk of heart failure hospitalizations and improving symptoms are key therapeutic goals in the treatment of heart failure. We are particularly pleased by the consideration of Ferinject® and Veltassa® in the new treatment guidelines to achieve these therapeutic goals and believe this will enable us to further expand our role in helping heart failure patients with iron deficiency and hyperkalemia live better, healthier lives.”
The ESC HF guidelines aim to provide practical, evidence-based recommendations for the diagnosis and treatment of HF, thereby improving and harmonizing standards of diagnosis and treatment of cardiovascular diseases for physicians, and potentially optimizing patient care. The ESC HF guidelines are updated periodically, with the 2021 version published at the virtual ESC congress end of August 2021.
The 2021 ESC guidelines are published under: www.escardio.org/Guidelines
About Vifor Pharma Group
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com .
About AFFIRM-AHF
The AFFIRM-AHF study was a multi-center, randomized, double-blind, placebo-controlled trial, comparing the effect of intravenous ferric carboxymaltose (FCM) on hospitalizations and mortality in iron deficient patients admitted for acute heart failure. The study demonstrated that administration of Ferinject®
reduced the risk of HF hospitalizations and improved quality of life with no apparent effect on the risk of cardiovascular death.
About Ferinject®
Ferinject®
/Injectafer®
(ferric carboxymaltose) is a leading i.v. iron therapy with market authorization in 84 countries by the end of June 2021. More than 16 million patient years of experience have helped to establish Ferinject®
/ Injectafer®
as a trusted brand, with clinical benefits demonstrated by its efficacy and safety data2
.
About Veltassa®
Veltassa®
(patiromer) is a potassium binder approved for the treatment of hyperkalemia. Veltassa®
was specially designed to exchange calcium rather than sodium for potassium ions, ensuring suitability for patients who cannot tolerate even small increases in sodium. Veltassa®
should not replace emergency treatment for life-threatening hyperkalemia.
References:
1
Anker, S.,D. (2018). Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient meta-analysis. Eur J Heart fail. 20(1):125-133. doi: 1002/ejhf.823.
2
Scott Drugs. 2018 Mar;78(4):479–493. doi: 10.1007/ s40265-018-0885-7.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210830005519/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phenom Adds Major Headline Speakers as IAMPHENOM Europe Approaches Sold-Out Status6.10.2026 15:30:00 CEST | Press release
Second wave of esteemed speakers to bring real-world guidance on applying AI, agents and automation to improve hiring, development and retention Phenom, the leader in applied AI built to redesign work operations for hiring faster, developing better and retaining longer, today announced the newest wave of speakers for IAMPHENOM Europe 2026, the only applied AI event dedicated to human resources taking place on 4-5 November in Paris, France. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261006714151/en/ Phenom announced the newest wave of speakers for IAMPHENOM Europe 2026, the only applied AI event dedicated to human resources taking place on 4-5 November in Paris, France. The two-day conference gives attendees what other HR events can’t: an inside look at AI agents already in production, automated workflows tailored to specific business contexts and the dramatic results they are already delivering. Across keynotes, customer
European Firms Struggle to Keep Pace with Growing DSAR Demands, New Reveal Study Finds6.10.2026 15:00:00 CEST | Press release
With 86% of organisations still lacking dedicated DSAR technology, fewer than half of requests are completed within the one-month window GDPR requires, even as spending climbs New research published today byReveal, the provider of integrated AI-native platforms spanning the dispute resolution lifecycle, found that large European organisations complete fewer than half of data subject access requests (DSARs) within the one-month deadline required under the General Data Protection Regulation (GDPR), a shortfall the study ties directly to a near-universal absence of purpose-built technology. Nearly nine in 10 organisations still run DSARs on manual or general-purpose workflows, with no dedicated tooling in place. The report, based on a survey of 213 legal and privacy professionals at large European enterprises, is the first of its kind to benchmark how organisations across the region are managing DSAR compliance at scale. The findings expose structural inconsistencies between how organisat
New Global Survey Finds Majority of VMware Users Are Choosing Alternative Paths for Cost Control, Roadmap Flexibility and Better Support6.10.2026 15:00:00 CEST | Press release
Rimini Street and DBTA/Unisphere Research survey finds 66% are already using or are considering third-party support Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced findings from the 2026 IT Virtualization Survey – What’s Next for VMware Users, a new global survey of nearly 300 VMware user organizations conducted by Unisphere Research on behalf of Rimini Street. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261006014490/en/ New Global Survey Finds Majority of VMware Users Are Choosing Alternative Paths for Cost Control, Roadmap Flexibility and Better Support Cost Cited as the Number One Factor in Seeking Alternative VMware Solutions Key Findings: 90% of respondents said they are considering alternatives to VMware due to higher licensing costs, while 54% cited the end of perpetual license supp
Xsolla Shows Brand Owners How to Create Value for Video Players at Brand Licensing Europe With Rewarded Marketing6.10.2026 15:00:00 CEST | Press release
Twenty-One Years of Game Commerce Comes to ExCeL London, October 6 to 8, With a New Way for Brands to Reward the Players They Have Been Trying to Reach for Years Xsolla, a global commerce company, today announced it will be at Brand Licensing Europe 2026 at ExCeL London, October 6 to 8, to show brand owners how to engage with video game players by creating quest-based programs and value new users actually value. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261006443167/en/ Graphic: Xsolla Video games are one of the largest categories of entertainment spending in the world, yet most brands still treat the category as an experiment: a one-off promotional stunt or a single media buy, not a lasting engagement program. The traditional formats brands default to were never built for players. Interstitial pop-ups disrupt gameplay, banner ads go unnoticed, and in-game activations remain cumbersome and expensive to execute. The idea
Rochester Electronics Launches Localized E-Commerce Experiences Across Key Global Markets6.10.2026 15:00:00 CEST | Press release
Europe and the Americas join Rochester's growing global e-commerce network Rochester Electronics today announced the launch of fully enabled e-commerce capabilities across its regional websites, allowing customers in key global markets to search for, source, and purchase authorized semiconductors in their local language. While Rochester's regional sites previously offered localized content and product information, they now support a complete end-to-end purchasing experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261006914131/en/ Rochester Electronics Launches Localized E-Commerce Experiences Across Key Global Markets The newly upgraded platforms are now live in Portuguese (Brazil), Spanish (Mexico), French, German, Italian, and Polish, complementing Rochester’s existing full e-commerce platforms in English, Chinese, Japanese, and Korean (South Korea). Customers can now complete transactions directly through their lo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom